

ADNI2 Private Partner Scientific Board (PPSB)

Adam Schwarz (Eli Lilly), PPSB Chair

March 18, 2013



FNIH

Foundation for the
National Institutes of Health

Coordination and Organization by FNIH

Paris L. A. Moore
Partnership Development Officer
(301) 443-2103
pmoore@fnih.org

Erika D. Tarver
Project Officer
(301) 594-9255
etarver@fnih.org

Andrea Baruchin, Ph.D.
Senior Advisor to the President
(301) 594-6649
abaruchin@fnih.org

Current ADNI2 PPSB Partners



BIOLINICA™

biogen idec

Bristol-Myers Squibb



Genentech
IN BUSINESS FOR LIFE



Johnson & Johnson



NeuroRx
RESEARCH

NOVARTIS



SYNARC
Start here, finish first.™



Canadian Institutes of Health Research

Instituts de recherche en santé du Canada

alzheimer's association®



Alzheimer's
Drug Discovery
Foundation

Private partners committed more than \$48M to AD research through ADNI1 and ADNI2



Foundation for the National Institutes of Health

Benefits of PPSB Partnership

- Membership in the ADNI Private Partner Scientific Board (PPSB)
 - Independent, pre-competitive forum for study-related scientific exchange among partners; convened monthly by the FNIH
 - Receive latest updates on ADNI progress/status
 - Representatives attend annual face-to-face ADNI Steering Committee meeting
 - Chair serves as liaison to ADNI Executive Committee
- Participate in ADNI Core open discussions (Biomarkers, Biostatistics, Clinical, Genetic, Informatics, MRI, Neuropathology, PET, Publications)
- Interact with NIH, FDA, ADNI PI/Core Leaders and industry colleagues
- Participate in industry-initiated Working Groups
- Participate in annual PPSB face-to-face meetings (Spring and Fall)

ADNI Cores

PPSB Core Liaisons

PPSB working groups

Biochemical Biomarker
Les Shaw and John
Trojanowski

Holly Soares
(Johannes Streffer)

Biostatistics
Laurel Beckett

David Shera

Clinical
Ron Petersen & Paul Aisen

Veronika Logovinsky
(Nandini Raghavan)

Genetics
Andy Saykin

Enchi Liu
(Xiaolan Hu)

MRI
Cliff Jack

Pat Cole
(Adam Schwarz)

Neuropathology
John Morris

Enchi Liu
(Robert Paul)

PET
Bill Jagust

Mark Schmidt
(Rick Margolin)

Publications
Robert Green

Lee Honigberg

Informatics
Art Toga

RARC
Tom Montine

Enchi Liu
(Holly Soares)

P

P

S

B

Biofluid Biomarkers WG
Holly Soares, Johannes Streffer

Clinical Endpoints WG
Veronika Logovinsky, Nandini Raghavan

PET Endpoints WG
Mark Schmidt

ADAS-Cog Plus WG
Mark Schmidt, Holly Posner

Abeta as a Biomarker WG
Jeff Waring

Informatics WG
TBD

rsfMRI
Adam Schwarz

ADNI PI
Mike Weiner

PPSB Chair
Adam Schwarz

Ongoing Efforts of PPSB

- Commit more than \$48 million to AD research through ADNI1 and ADNI2
- Identify potential partners for PPSB
 - Araclon Biotech is the newest PPSB partner (May 2013)
- Participate in national research forums to discuss role of public-private partnerships in Alzheimer's research
 - NIA Alzheimer's Disease Research Summit (May 2012)
 - NIA Enabling Partnerships for AD Drug Development meeting (April 2013)
- 2013 objectives:
 - Plan Spring and Fall PPSB face-to-face meetings
 - Prosecute goals of working groups
 - Elect 2014 chair

PPSB face-to-face meeting, Oct 25-26

Bethesda, MD

■ **Draft agenda:**

- *Friday Oct 25 (p.m.):*
 - Clinical Endpoints working group updates /discussion
 - Clinical instruments for prodromal and presymptomatic populations

- *Saturday Oct. 26:*
 - Genetics update/discussion
 - Dependence of clinical trajectory on amyloid status
 - Other TBD

Interest in WW-ADNI initiatives

- US ADNI has provided an unprecedented forum for precompetitive discussion and advancement of the field in biomarkers and clinical trial methodologies.
- A key factor in this success has been ready access to the data.
- WW-ADNIs could provide additional potential data sets of enormous utility:
 - Independent data sets for replication
 - Other geographies/ethnicities
 - Important in planning global clinical trials.